tiprankstipranks
Trending News
More News >
Pak Fah Yeow International Limited (HK:0239)
:0239
Hong Kong Market

Pak Fah Yeow International Limited (0239) AI Stock Analysis

Compare
2 Followers

Top Page

HK

Pak Fah Yeow International Limited

(0239)

Rating:70Outperform
Price Target:
HK$2.50
▲(0.81%Upside)
The stock's strong valuation, indicated by a low P/E ratio and high dividend yield, is the most significant factor driving the overall score. While the financial performance shows strong profitability and a robust balance sheet, declining revenue and net profit margins present challenges. Technical analysis indicates neutral market conditions with slight positive momentum.

Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)

Pak Fah Yeow International Limited Business Overview & Revenue Model

Company DescriptionPak Fah Yeow International Limited (0239) is a Hong Kong-based company primarily engaged in the manufacturing and distribution of healthcare products. The company is best known for its flagship product, White Flower Embrocation, a medicated oil used for relief of pain and various ailments. Pak Fah Yeow operates in the healthcare sector, focusing on traditional medicated oils and related products.
How the Company Makes MoneyPak Fah Yeow International Limited generates revenue through the production and sale of its healthcare products, primarily the White Flower Embrocation. The company sells its products domestically in Hong Kong and internationally across various markets, including Southeast Asia, North America, and Europe. Revenue streams are derived from direct sales to consumers through retail channels, as well as distribution agreements with wholesalers and retailers. The company may also engage in marketing partnerships or sponsorships to increase brand visibility and product reach. With a strong brand legacy and recognition, Pak Fah Yeow leverages its traditional formulation to maintain a loyal customer base and sustain its revenue.

Pak Fah Yeow International Limited Financial Statement Overview

Summary
The company has strong profitability margins and a robust balance sheet with minimal leverage. However, declining revenue and net profit margin, along with incomplete cash flow data for 2024, indicate potential operational and liquidity challenges.
Income Statement
65
Positive
The company demonstrated a mixed financial performance. While the EBIT margin was strong at 41.42% and EBITDA margin at 56.19% in 2024, the net profit margin declined to 33.11% from 40.50% in 2023. Revenue in 2024 showed a negative growth rate of -8.43% compared to 2023, indicating challenges in maintaining revenue growth.
Balance Sheet
78
Positive
The balance sheet is robust, with a low debt-to-equity ratio of 0.01, indicating minimal leverage. The equity ratio stands at a healthy 86.77%, reflecting strong asset backing. However, the return on equity decreased to 10.75% in 2024 from 13.73% in 2023, showing a decline in profitability on equity.
Cash Flow
60
Neutral
Cash flow analysis is limited due to missing data for 2024. In 2023, the operating cash flow to net income ratio was 1.41, indicating efficient conversion of profits into cash flow. Free cash flow growth was not calculable for 2024 due to unavailable data, presenting a challenge in assessing cash flow trends.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue236.91M259.31M147.20M139.82M109.34M
Gross Profit203.20M167.59M74.06M68.71M41.48M
EBITDA105.73M136.81M53.71M52.20M-25.22M
Net Income78.63M105.04M29.95M38.19M-38.36M
Balance Sheet
Total Assets843.35M907.47M823.14M837.75M795.40M
Cash, Cash Equivalents and Short-Term Investments290.02M277.61M180.34M178.28M131.48M
Total Debt4.20M4.74M5.50M16.21M17.86M
Total Liabilities111.45M142.28M115.91M130.03M122.20M
Stockholders Equity731.91M765.18M707.23M707.72M673.19M
Cash Flow
Free Cash Flow78.02M144.84M39.76M69.54M7.62M
Operating Cash Flow78.96M147.90M39.92M70.36M8.26M
Investing Cash Flow-3.19M16.65M-6.67M-565.00K-637.00K
Financing Cash Flow-67.54M-48.96M-33.91M-22.41M-29.07M

Pak Fah Yeow International Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.48
Price Trends
50DMA
2.39
Positive
100DMA
2.36
Positive
200DMA
2.40
Positive
Market Momentum
MACD
0.03
Negative
RSI
64.39
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 2.46, above the 50-day MA of 2.39, and above the 200-day MA of 2.40, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 64.39 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0239.

Pak Fah Yeow International Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
HK$1.17B5.83
2.93%2.82%21.63%
70
Outperform
HK$788.45M10.0310.50%15.02%-8.64%-25.13%
70
Outperform
HK$745.36M7.218.81%5.68%5.79%-43.49%
60
Neutral
HK$15.31B5.72-7.43%4.61%11.60%-21.06%
55
Neutral
HK$388.16M54.760.55%8.70%-66.75%-83.83%
49
Neutral
HK$286.74M-40.39%-43.73%-434.56%
47
Neutral
HK$197.47M-26.80%-6.09%66.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0239
Pak Fah Yeow International Limited
2.64
0.38
16.81%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.86
-0.32
-27.12%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.38
-0.67
-63.81%
HK:1498
PuraPharm Corp. Ltd.
0.49
-0.24
-32.88%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.30
0.12
66.67%
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.17
0.97
80.53%

Pak Fah Yeow International Limited Corporate Events

Pak Fah Yeow International Limited Updates Nomination Committee Terms
Jun 30, 2025

Pak Fah Yeow International Limited has revised the terms of reference for its Nomination Committee, effective from July 1, 2025. This update emphasizes the importance of diversity and independence within the committee, requiring a majority of members to be independent non-executive directors and ensuring gender diversity. The committee is tasked with meeting at least annually to oversee the nomination process, thereby potentially enhancing the company’s governance structure and stakeholder confidence.

Pak Fah Yeow International Limited Announces Successful AGM Resolutions
Jun 16, 2025

Pak Fah Yeow International Limited announced the successful passage of all resolutions at its annual general meeting held on June 16, 2025. Key resolutions included the approval of financial statements, declaration of final and special dividends, re-election of directors, and granting of mandates for share repurchase and issuance, reflecting strong shareholder support and strategic direction for the company.

Pak Fah Yeow International Limited Announces AGM and Share Repurchase Plan
Apr 17, 2025

Pak Fah Yeow International Limited has announced its upcoming annual general meeting scheduled for June 16, 2025, in Hong Kong. Key agenda items include the consideration of financial statements for the year ending December 2024, the declaration of a final and special dividend, re-election of directors, and the re-appointment of auditors. Additionally, the company seeks approval for a share repurchase program, allowing the repurchase of up to 10% of its issued shares, which could impact its market positioning and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025